New data boosts Janssen's Stelara submission for Crohn's disease

Janssen, a subsidiary of US health care giant Johnson & Johnson (NYSE:JNJ) has presented new data from Phase III trials of its Crohn’s disease treatment Stelara (ustekinumab).

The new findings from the pivotal IM-UNITI study show that a significantly greater proportion of adult patients with moderate to severe Crohn’s disease who received Stelara subcutaneous (SC) maintenance therapy were in clinical remission at one year.

The study tested 388 patients who achieved clinical response eight weeks after a single intravenous infusion of ustekinumab in the UNITI-1 and UNITI-2 Phase III induction studies.